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Abstract
Background: At present, no clear evidence has been provided regarding the superiority of various heparin regimens as bridging treatment after heart surgery in 
patients who need chronic anticoagulation.
Objectives: Aim of present pilot investigation was to prospectively compare the safety of weight adjusted enoxaparin and subcutaneous unfractionated heparin in 
patients undergoing valvular heart surgery.
Methods: Patients undergoing heart valve surgery were randomized to weight adjusted enoxaparin (group I) or comparable weight adjusted subcutaneous unfractionated 
heparin (group II) started within 12 hours after ICU admission. As control group in the same period patients undergoing isolated CABG were randomized to either 
treatment (group III and IV). Hemorrhagic and thromboembolic complications, the need for blood transfusions, total drainage fluid, haemoglobin values and 
presence and degree of pericardial effusion at discharge were evaluated. 
Results: 184 patients were included in the study 69 in group I and 115 in group II. Twenty and respectively 49 patients were enrolled in the control groups. Average 
fluid drainage after 24 hours was similar with the two regimens both in study and control group. A trend towards the need of blood unit transfusion in ICU after 
starting heparin therapy was higher in patients treated with. s.c. unfractionated heparin vs enoxaparin (40 vs. 30% p<0.05). No thromboembolic events were recorded. 
Hemorrhagic pericardial effusion requiring surgical drainage was more frequent with unfractionated heparin (7 vs. 1) however all patients went to our observation 
after treatment withdrawal, usually between 10 and 17 days after surgery and all but one had anticoagulant over dosage (average INR 4.53). In control groups only 
one patient needed pericardiocentesis. 
Conclusion: In patients who need prolonged oral anticoagulation hospital bridging treatment with weight adjusted enoxaparin seems as safe as weight adjusted s.c 
unfractionated heparin with a lower rate of blood transfusion and a lower rate of pericardial effusion and need for pericardial drainage.
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Backgound 
After heart valve surgery requiring prolonged anticoagulation 
no clear evidence has still been provided regarding the safer and 
more effective bridging anticoagulant treatment to be started on first 
postoperative day and prosecuted until full effectiveness of vitamin K 
antagonist treatment [1] . The risk of bleeding early after surgery must 
be faced to the risk of thromboembolic events in the subsequent days. 
Unfractionated heparin (UFH) has for a long term been the standard 
bridging anticoagulant drug [2], however low-molecular-weight 
heparin (LMWH) may be as safe and effective without increase of 
bleeding risk [3]. LMWH has more predictable and rapidly reached 
anticoagulation due to its better Few studies have analyzed LMWH as a 
bridging anticoagulant after valve replacement or repair [4-6]. 
The purpose of present pilot investigation was to prospectively 
compare the safety of weight adjusted enoxaparin and subcutaneous 
unfractionated heparin in patients undergoing valvular heart 
surgery.
Method
From January to June 2012, 214 patients underwent heart valve 
surgery at our institution. Exclusion criteria from the study were a 
recent neurologic event, pre- or post-operative severe renal insufficiency 
(serum creatinine >200 μmol/L), dialysis, aortic dissection, critical 
perioperative state, intraaortic balloon counter pulsation or duration of 
intubation of more than 48 hours. 184 patients were therefore included 
in the investigation. 
Study design
After surgery, they were randomized to weight adjusted enoxaparin 
(January-March) or comparable weight adjusted subcutaneous 
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unfractionated heparin (April –June) started within 12 hours after ICU 
admission. As control group in the same period patients undergoing 
isolated CABG were randomized to either treatment (group III and IV). 
Postoperative anticoagulation protocol was started on 
postoperative day 1, with 1 weight adjusted subcutaneous enoxaparin 
or sc UFH injection per day (Table 1). Oral anticoagulation (warfarin) 
was started as soon as drainage tubes were removed. On postoperative 
day 2, subcutaneous enoxaparin and UFH were administered at 12-
hour intervals. LMWH and sc UFH was given until the International 
Normalized Ratio (INR) was within the target range for 2 consecutive 
days (INR 2 to 3 after aortic valve replacement or 2.5 to 3.5 after mitral or 
tricuspid valve replacement). Antiplatelet therapy was only prescribed 
in case of concomitant peripheral vascular disease or coronary 
artery disease. Echocardiography was systematically performed 
prior to discharge, usually on post-operative day. Hemorrhagic and 
thromboembolic complications, the need for blood transfusions, 
total drainage fluid, hemoglobin values and presence and degree of 
pericardial effusion at discharge other than the need for pericardial 
drainage were evaluated. Written informed consent was obtained at 
hospital admission. The study was approved by Ethical Committee of 
the Azienda Ospedaliera Universitaria Careggi, Firenze. 
End-points
The primary end points of this study were the occurrence of a 
thromboembolic (efficacy end point) or major bleeding (safety end 
point) event during the 4-week follow-up. Thromboembolic events 
were defined as a transient or permanent stroke, peripheral embolism 
or valve thrombosis. Major bleeding events were defined as any bleeding 
requiring transfusion, surgical operation, or prolonged hospitalization 
or rehospitalization
Statistical analysis
The data are presented as the mean ± standard deviation (SD). 
Differences between the categorical variables were tested using Fisher’s 
exact test. Differences between continuous variables were tested using 
the Student’s t-test. A P-value of less than 0.05 was considered to be 
statistically significant. 
Perioperative variations in the hemoglobin level, haematocrit 
in drainage fluid, fluid drainage at 24 hours, mean unit of blood 
transfused were analyzed using a one-way repeated ANOVA test. The 
statistical computations were performed using SPSS (SPSS® version 
17.0, Chicago, IL).
Results
Baseline demographic, clinical and operative characteristics are 
reported in Table 2 and 3 
During the 4 weeks after surgery, no patients had thromboembolic 
event thus suggesting that both enoxaparin and sc UH may be 
efficient as bridge therapy in patients with indication to long term oral 
anticoagulation. We found a trend towards a higher fluid drainage after 
24 hours in patients treated with unfractionated heparin in comparison 
to LMWH. A similar trend was found also in control group e.g patients 
undergoing isolated myocardial revascularization. The need for 
blood transfusion in ICU and during the whole hospital stay was not 
significantly different in the two groups although UFH showed a trend 
for a higher need (Table 4). There was no difference in haemoglobin 
levels at discharge between patients treated with UFH and LMWH. At 
hospital discharge, there was no significant difference in the incidence 
of mild to moderate pericardial effusion in patient treated with dose 
adjusted UH in comparison to patients in LMWH (18 % vs. 19% 
respectively). Hemorrhagic pericardial effusion requiring drainage 
however was significantly more frequent in patients treated with 
unfractionated heparin (6.1%) than with enoxaparin (1.8%) (Table 5). 
Pericardial drainage was performed in 3 group II (UFH) patients before 
hospital discharge, while the other procedures were performed largely 
after treatment withdrawal, between 10 and 17 days after surgery. All 
but one patients had INR was above therapeutic level (average value 
4.53). No heparin-induced thrombocytopenia was diagnosed during 
the follow-up period. 
Discussion
The bridging regimen after heart surgery needing long term oral 
anticoagulation is still not clearly defined [7-9]. ESC guidelines [10] 
suggest that oral anticoagulation should be started during the first 
Weight (kg) Enoxaparin dose Sc UFH dose
< 50 2000 5000
50-69 3000 7500
70-89 4000 12500
>90 6000 12500
Table 1. Heparin dosage 
Characteristics LMWH UH
N 69 115
Age (years ± SD) 69.4 (±11.3) 68.1 (±11.8)
Hypertension (%) 49 (59) 70  (56.43)
FA history (%) 18 (26) 39 (33)
LA diameter (mm) 44.65  ±6.8) 43.,96   ±7.1
LVEF (%) 51.3  ±10.5 51.9  ±12.2
β – Blockers (%) 55 (79) 83  (72)
Ace- inhibitors or AT1 – 
blocker (%)
61(88) 103 (89)
Table 2. Clinical characteristics of patients
ENOXAPARIN                   sc UFH
No CABG CABG NO-CABG CABG
AORTIC VALVE 
REPLACEMENT 13 10 24 15
AORTIC ROOT SURG. 
(main Bentall)
11 18
MITRAL VALVE SURGERY 
(75% MV repair) 14 5 24 9
MITRAL AND AORTIC 
REPLACEMENT 7 5 11 10
OTHER 3 4
Table 3. Type of surgery 
GROUP I 
LMWH
GROUP II SC 
UHEP
GROUP III 
LMWH CABG
GROUP IV
UHEP CABG
Haematocrit %
in drainage fluid
8 hours PO
12.7 ± 6.5 13.9 ± 13.4 15.3 ± 7.3 12.7 ± 7.8
Haematocrit %
in drainage fluid 
16 hours PO
8.3 ± 5.1 8.4 ± 6.3 8.2 ± 5.1 7.5 ± 4.9
Fluid drainage at 
24 hours (ml)
418.4 ± 210 469 ± 299 409 ± 230 510 ± 291
Mean Blood 
Unit transfused
1.2 ± 1.3 1.9 ± 2.4 0.7 ± 0.9 0.9 ± 1.2
Haemoglobin at 
discharge 10.2 ±  1.23 10.3 ± 2.2 10.4 ± 1.4 10.3 ± 1.7
Table 4. Haematocrit % in drainage fluid,  total fluid drainage at 24 hours , mean blood. 
Unit transfused and mean haemoglobin at discharge in the 4 groups under investigation. 
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postoperative days. Intravenous unfractionated heparin (UFH), 
monitored to an activated partial thromboplastin time (aPTT) of 1.5–
2.0 times control value, enables rapid anticoagulation to be obtained 
before the INR rises. Low molecular weight heparin (LMWH) seems 
to offer effective and stable anticoagulation and has been used in small 
observational series but there are few randomized trials supporting this 
practice [4]. In the case of LMWH administration anti-Xa monitoring 
is recommended by guidelines. AHA/ACC guidelines [11] indicates 
that bridging anticoagulation is typically started once postoperative 
bleeding is no longer an issue. Some centers use subcutaneous low-
molecular-weight heparin (LMWH) or unfractionated heparin (UFH), 
whereas other centers continue to prefer intravenous UFH.
In our prospective randomized study, we compared weight adjusted 
enoxaparin with weight adjusted subcutaneous unfractionated heparin. 
Result from this investigation suggest that that the administration of 
enoxaparin as a bridging therapy immediately after heart valve surgery 
requiring long term anticoagulation is effective, and safe as sc UFH 
Major bleeding and in particular haemorrhagic pericardial effusion with 
the need for pericardial drainage have been recorded more frequently 
in the subgroup of patients treated with UH. This finding however 
may be considered with caution since > 50% of haemo -pericardium 
requiring pericardial drainage occurred late, after hospital discharge 
to rehabilitation centres, and all, except one, had INR largely above 
therapeutic range. In our anticoagulation protocol, only prophylactic 
enoxaparin and UFH were given on postoperative day 1 to reduce 
the risk of bleeding. Indeed, significant haemostasis alterations 
were reported during the first 24 hours following cardiopulmonary 
bypass surgery Vitamin K agonist therapy generally began on the 
first postoperative day to ensure a shorter LMWH anticoagulation 
bridging duration. This may explain the absence of heparin- induced 
thrombocytopenia in our study. 
Our findings, in terms of thromboembolic and major bleeding 
event rates, are consistent with those previously reported based 
on the use of UH or LMWH anticoagulation therapy after heart 
surgery. Subcutaneous enoxaparin was used as bridging anticoagulant 
treatment in a prospective registry of patients who underwent cardiac 
surgery between December 2003 and June 2004 and required long-term 
anticoagulation [4]. The mean (SD) number of days between surgery 
and the first dose of anticoagulant was 2.01 for acenocumarol and 1 for 
enoxaparin. The mean (SD) daily dose of enoxaparin was 1.1 (0.27) mg/
kg. Six thromboembolic events (4.3%; 95% CI 1.6 to 9.1) occurred, but 
only four of them were plausibly related to enoxaparin (2.9%; 95% CI 0.8 
to 7.1). Six major hemorrhagic events (4.3%; 95% CI 1.6 to 9.1) occurred, 
but only three were plausibly related to enoxaparin (2.1%; 95% CI 0.4 
to 6.1). Bucci et al. [6] in a retrospective study compared dalteparin 
(n = 100) as postoperative anticoagulant with UFH (n = 103). Overall, 
there were for fewer thrombotic events in the LMWH-treated group 
(4% vs. 11%, p = 0.11). There was a higher rate of bleeding events in 
the UFH-treated group (10% vs. 3%, p = 0.08). Six patients in the UFH-
treated group developed HIT, 4 of whom had thrombotic events (HIT 
with thrombosis). In the LMWH-treated group, 3 patients developed 
HIT, 1 of whom had HIT with thrombosis. In the study by Fanikos 
et al. [12] compared efficacy, safety, and cost of low-molecular-weight 
heparin with continuous-infusion unfractionated heparin for initiation 
of anticoagulation after mechanical prosthetic valve implantation. 
Patients who received low-molecular-weight heparin had a shorter 
length of stay and decreased postoperative costs compared with the 
control subjects receiving unfractionated heparin. Significantly more 
bleeding complications in the warfarin plus  heparin  group versus 
warfarin group as evidenced by higher rates of pericardial effusions 
(24% vs. 8%, p = 0.02) and reoperation for bleeding (8% vs. 0%, p = 
0.05) was reported in retrospective study evaluating differences in 
bleeding and thrombotic events between a homogenous group of 
patients undergoing mechanical aortic  valve  replacement who either 
received or did not receive intravenous unfractionated  heparin  or 
subcutaneous low-molecular weight heparin  as  bridging  strategy 
to warfarin  therapy [13] . Logistic regression analysis identified 
group assignment (warfarin plus heparin versus warfarin only) to be 
significantly associated with the odds of bleeding (odds ratio 4.46, 95% 
confidence interval:1.42 to 14.02, p  = 0.01). A recent meta-analysis 
including twenty-three studies (9534 patients) reported bleeding rates 
of 1.8% (95% confidence interval CI  1.0-3.3) in the  group receiving 
OAC, 2.2% (95%  CI  0.9-5.3) in the OAC  +  UFH group, and 5.5% 
(95% CI 2.9-10.4) in the OAC + LMWH group (P = 0.042) [14]. The 
thromboembolic event rate was 2.1% (95%  CI  1.5-2.9) in the group 
receiving OAC, as compared with 1.1% (95% CI 0.7-1.8) of OAC + UFH 
and OAC + LMWH (P = 0.035).
Limitations of the study 
The small number of patients included in present study hampers 
conclusive statements about the efficacy and safety of low molecular 
weight heparin as bridging therapy to oral anticoagulants after heart 
surgery. However present results confirm the observations of most of 
previous investigations as reported in the discussion section. Due to the 
protocol of randomization, for chance, the number of patients included 
in the enoxaparin group was about one third of overall population 
under investigation, nevertheless the clinical characteristics of the two 
groups did not differ significantly. At variance with previous studies 
in present investigation we included patients undergoing different 
surgical procedures, all needing long – term oral anticoagulation, at 
different risk of bleeding and thromboembolic complications in order 
to have more adherence to real world conditions. 
Conclusion 
Results from present pilot study suggest that patients who need 
prolonged oral anticoagulation in hospital bridging treatment 
with weight adjusted enoxaparin seems as safe as weight adjusted 
s.c unfractionated heparin with a lower rate of blood transfusion 
and a lower rate of pericardial effusion and need for pericardial 
drainage. Larger trials are necessary to establish the clinical relevance 
of bridging therapy and the safety of LMWH.
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GROUP 
I LMWH 
n=69
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drainage 1 7 1 -
Table 5. Pericardial complications in the 4 groups 
Rostagno C (2017) Bridging therapy to chronic anticoagulant treatment in patients undergoing cardiac surgery: comparison between low-molecular-weight heparin 
and subcutaneous unfractionated heparin. A pilot study
 Volume 1(1): 4-4Blood Heart Circ, 2017          doi: 10.15761/BHC.1000103
9. Sun JC, Davidson MJ, Lamy A, Eikelboom JW (2009) Antithrombotic management of 
patients with prosthetic heart valves: current evidence and future trends. Lancet 374: 
565-576. [Crossref]
10. Guidelines on the management of valvular heartdisease (version 2012) (2012) The Joint 
Task Force on the Management of Valvular Heart Disease of the European Society of 
Cardiology (ESC) and the EuropeanAssociation for Cardio-Thoracic Surgery (EACTS) 
European Heart Journal 33: 2451-2496. [Crossref]
11. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP (2014) 2014 AHA/ACC 
guideline for the management of patients with valvular heart disease: a report of the 
American College of Cardiology/American Heart Association Task Force on Practice 
Guidelines. J Am Coll Cardiol 63: e57-185 [Crossref]
12. Fanikos J, Tsilimingras K, Kucher N, Rosen AB, Hieblinger MD, et al. (2004) 
Comparison of efficacy, safety, and cost of low-molecular-weight heparin with 
continuous-infusion unfractionated heparin for initiation of anticoagulation after 
mechanical prosthetic valve implantation. Am. J. Cardiol. 93: 247-250. [Crossref]
13. Guglielmetti LC, Sorabella R, Chiuzan C, Najjar M, Castillero E, et al. (2016) 
Bridging Anticoagulation After Mechanical Aortic Heart Valve Replacement: A 
Questionable Routine. Ann Thorac Surg 102: 48-54. [Crossref]
14. Passaglia LG, de Barros GM, de Sousa MR (2015)  Early 
postoperative bridging anticoagulation after mechanical heart valve replacement: a 
systematic review and meta-analysis. J Thromb Haemost 13: 1557-67. [Crossref]
3. Montalescot G, Polle V, Collet JP, Leprince P, Bellanger A, et al. (2000) Low molecular 
weight heparin after mechanical heart valve replacement. Circulation 101: 1083-1086. 
[Crossref]
4. Rivas-Gándara N, Ferreira-González I, Tornos P, Torrents A, Permanyer-Miralda G, et 
al. (2008) Enoxaparin as bridging anticoagulant treatment in cardiac surgery. Heart 94: 
205-210. [Crossref]
5. Meurin P, Tabet JY, Weber H, Renaud N, Ben Driss A (2006) Low-molecular-weight 
heparin as a bridging anticoagulant early after mechanical heart valve replacement. 
Circulation 113: 564-569. [Crossref]
6. Bucci C, Geerts WH, Sinclair A, Fremes SE (2011) Comparison of the effectiveness and 
safety of low-molecular weight heparin versus unfractionated heparin anticoagulation 
after heart valve surgery. Am J Cardiol 107: 591-594. [Crossref]
7. Stein PD, Alpert JS, Bussey HI, Dalen JE, Turpie AG (2001) Antithrombotic therapy in 
patients with mechanical and biological prosthetic heart valves. Chest 119: 220S–227S. 
[Crossref] 
8. Schlitt A, von Bardeleben RS, Cannegieter SC, Rosendaal FR, Wintzen AR, et al. 
(1995) Optimal oral anticoagulant therapy in patients with mechanical heart valves. N 
Engl J Med 333: 11-17. [Crossref]
Copyright: ©2017 Rostagno C. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted 
use, distribution, and reproduction in any medium, provided the original author and source are credited.
